Atlassian Corp is surging on a strong earnings report.
The software company reported its Q4 and full results for fiscal year 2022 after Thursday's closing bell.
Atlassian reported adjusted net income of $0.27 per diluted share, marking a modest increase from the year-earlier quarter's $0.24 EPS.
Revenues came in at $759.8 million for the quarter, up from $559.5 million a year earlier.
Both figures topped the Street's target of $0.26 EPS on revenues of $724.3 million.
Atlassian's Q1 guidance also topped analysts' expectations.
TEAM is leading the Nasdaq-100 with a 10.5% gain on active volume.
Our Take: Solid growth for this large-cap software stock, but the company isn't as strong as it looks at first glance. Atlassian took a loss for the quarter, but its "adjusted" earnings showed a profit. I think there are better stocks in this sector.
Marker Therapeutics [MRKR] - Last Close: $0.33
Marker is up big today after announcing a key FDA approval.
The immuno-oncology firm said late Thursday that its investigational new drug (IND) application for its new non-Hodgkin lymphoma therapy was approved.
The FDA approval of Marker's IND for MT-601 means the company can move forward with designing and planning a clinical trial that will build upon the drug's Phase I/II TACTAL results.
Markerâs MT-601 Phase 1 trial will focus on r/r NHL patients who have failed CD19 CAR-T therapy, or those who are ineligible for treatment with those therapies.
The company plans to kick off its Phase 1 study of MTM-601 in 2023.
News of the FDA approval is lifting MRKR to a 99.3% gain on highly-active trading volume.
Our Take: Yellow put up solid Q2 numbers, but a tight labor market and record-high fuel costs are hitting the trucking and transportation industry hard. Yellow might not be feeling the heat just yet, but that could change very quickly.
